Drug intelligence / Profile preview

BMS-986120 + midazolam

Development stage: Discontinued
Lead developer: Bristol Myers Squibb
Modality: Small Molecules
Administration: Oral

Overview

BMS-986120 + midazolam is a drug combination used in clinical pharmacology studies to evaluate the drug-drug interaction potential of BMS-986120. BMS-986120 is a first-in-class, oral, small-molecule protease-activated receptor 4 (PAR4) antagonist developed by Bristol Myers Squibb for the treatment of arterial thrombosis and cardiovascular diseases. Midazolam is a short-acting benzodiazepine that serves as a sensitive probe substrate for the CYP3A4 enzyme. The co-administration of these agents in Phase I trials was intended to determine if BMS-986120 affects the pharmacokinetics of CYP3A4 substrates. Development of BMS-986120 has been discontinued.

Targets

GABRR (GABA-A receptor subunit rho)PAR4 (Protease-activated receptor 4)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)

Beyond the preview

Go deeper on BMS-986120 + midazolam.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986120 + midazolam.